Phase 4 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with early-stage or locally advanced breast cancer who are receiving a specific type of chemotherapy (called DD-AC/T) before or after surgery, and who need a type of medication called G-CSF to help prevent a serious infection risk related to low white blood cell counts
- People who are able to give verbal consent to participate
- People who are able to fill out questionnaires in either English or French
Who may not be able to join:
- People for whom the medications pegfilgrastim or filgrastim are not available before the trial begins
- People whose cancer has spread to other parts of the body (metastatic cancer)
- People who have a known allergic reaction or sensitivity to filgrastim, pegfilgrastim, or any of their ingredients
- People who have received certain cancer-killing (cytotoxic) chemotherapy treatments within the last 5 years
- People with ongoing or poorly controlled health conditions that the trial doctor believes could make it difficult to safely participate, or that could interfere with following the trial's requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xinni Song, MD, Ottawa Hospital Research Institute
Phone: 613-737-7700
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Patient-reported bone pain during cycle 1 of paclitaxel
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.